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CASE REPORT
TWO CASES OF VISCERAL LEISHMANIASIS IN COLOMBIA RESISTANT TO MEGLUMINE 
ANTIMONIAL TREATMENT
Iván Darío VÉLEZ(1), Lina María COLMENARES(1) & Carlos Aguirre MUÑOZ(2)
SUMMARY
Visceral leishmaniasis (VL) affects over 500 000 people worldwide each year. The disease occurs in the Mediterranean basin, 
Central and South America and is caused by Leishmania infantum (syn L. chagasi). VL is an endemic disease in Colombia, particularly 
along the Caribbean coast and the Magdalena River Valley and 90% of VL cases occur in children under the age of five. The first line 
of treatment is chemotherapy with pentavalent antimonial compounds, including sodium stibogluconate (Pentostam®) and meglumine 
antimoniate (Glucantime®). These compounds are the ones most used in Colombia, at a dose of 20 mg/kg/day for 28 days. Nevertheless 
resistance of L. infantum to pentavalent antimonials is becoming an important problem.
No cases of VL resistant to pentavalent antimonial compounds have previously been reported from Colombia. This report 
describes the two cases of VL resistance to antimonial compounds in a girl and a boy who did not respond to previous treatment with 
Pentacarinat® and Glucantime® regimens but were treated successfully with liposomal amphotericin B. Based on our findings, we 
recommend liposomal amphotericin B as the first line of treatment for VL due to its low toxicity, shorter administration period and 
the low price obtained by WHO. 
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INTRODUCTION
Visceral leishmaniasis (VL) caused by L. donovani and L. infantum 
affects over 500 000
 
people annually around the world12,23,25. VL due 
to L. donovani is an anthroponosis that mainly affects young adults in 
eastern Africa and India and typically produces post-kala azar dermal 
leishmaniasis (PKDL) after treatment. By contrast VL due to L. infantum 
mainly affects children and is a zoonosis whose reservoir is the dog. Its 
geographical distribution includes the Mediterranean basin as well as 
South and Central America13,22,23.
VL is endemic to Colombia, particularly along the Caribbean coast 
and the Valley of Magdalena River. It is caused by L. infantum transmitted 
by the bite of the phlebotomine sand flies Lutzomia evansi (Caribbean 
coast) and Lu. longipalpis (Magdalena River Valley)4,8,31.
The amastigotes of these Leishmania species replicate in 
macrophages from the liver, spleen, bone marrow and lymph nodes, 
causing severe and ultimately lethal lesions13. VL is usually fatal in the 
absence of effective treatment13,23.
Active VL may also represent relapse (recurrence 6-12 months after 
apparently successful treatment) or late reactivation (recrudescence) 
of subclinical or previously treated infection. Reactivation can be 
spontaneous but is often provoked by an intercurrent insult to T (CD4+) 
cell number or function-corticosteroid or cytotoxic therapy, antirejection 
treatment in transplant recipients, or advanced HIV disease13.
The first line of treatment involves the use of pentavalent antimonial 
compounds (SbV) such as sodium stibogluconate (Pentostam®) and 
meglumine antimoniate (N-metil-glucamine) (Glucantime®)5,9,13. 
Common side effects with sodium stibogluconate and meglumine 
antimoniate include abdominal pain, anorexia, vomiting, nausea, myalgia, 
arthralgia, headache, and malaise. Elevated amylase and lipase levels 
occur in most patients, but only a minority manifests clinically apparent 
pancreatitis. Persons with renal insufficiency seem to be at increased risk 
of this complication. Electrocardiographic changes are dose-dependent 
and include T-wave inversion and a prolonged QT interval. Arrhythmias 
and sudden death have been reported with doses greater than 20 mg of 
SbV/kg body weight/day. Pentavalent antimonials should be used with 
caution in elderly patients and those with heart disease, nephropathy 
and in pregnancy5,11,17. 
In Colombia, Glucantime® is currently used for VL at a dose of 
20 mg/kg/day during 28 days, according to guidelines from the Ministry 
of Health16.
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Although Colombia had not reported cases of VL resistant to 
pentavalent antimonials until now, this is already an important problem 
in Africa and India2,20,23,29. Primary resistance to SbV is seen in 
approximately 1% of cases in Africa and up to 60% in certain regions 
of India2,5. In India the recommended treatment for VL produced by L. 
donovani is Miltefosine®12,13,23,24,25, although there are no reports of the 
effectiveness on this medication in treating VL produced by L. infantum.
Several other compounds have been used successfully to treat 
VL patients. Amphotericin B deoxycholate (Fungisone®) is effective 
but requires parenteral administration over prolonged periods and is 
associated with nephrotoxicity and other side effects. Various doses and 
durations of therapy have been used, 1.0 mg per kg body weight per day 
for 15 days or 1.0 mg per kg body weight every other day for 30 days 
being two alternatives13,14,17,21. Pentamidine isethionate (Pentacarinat®) at 
2-4 mg/kg body weight/day for up to 15 days is an effective but potentially 
toxic option. Pentamidine has a number of side effects including 
hypotension, life-threatening hypoglycemia caused by pancreatic β-cell 
injury, and later insulin-dependent diabetes mellitus5,13,14,17,21. Aminosidine 
(Paromomycin), a parenterally administered aminoglycoside, (11 mg/kg 
daily for 21 days) has shown promise in some studies12,14,25,26,29. The 
imidazoles ketoconazole and itraconazole have been used successfully in 
some cases, but primary failures occur and they are not recommended for 
general use21,25. Allopurinol was ineffective for cutaneous leishmaniasis 
(CL) in Colombia30. Combined therapies of allopurinol and antimonials 
with interferon have also been tried in limited studies12,14,25.
Amphotericin B causes secondary effects such as renal 
disturbances, anemia, fever, malaise and hypokalemia5,14,17,25. During 
the past years, liposomes have been used to transport chemotherapeutic 
agents into macrophages, which are the target cells for Leishmania 
amastigotes, improving the efficacy of the treatment and reducing its 
toxicity5,17,22,25. Liposomal amphotericin B (Ambisome®) is highly 
effective for treating VL and has low toxicity, as different studies 
have demonstrated1,12,13,14,20,22,25.
Reports on the use of chemotherapy associated with immunotherapy 
have shown considerable efficacy in some cases of diffuse leishmaniasis 
using immunotherapy in American CL patients for whom antimonial 
drugs are restricted (elderly patients and those with other conditions, 
such as cardiopathy, nephropathy and pregnancy), an immunological 
stimulus associated with a chemotherapy treatment leading to a reduction 
in antimony volume required and treatment period. This complex provides 
substantial benefits to the patient, including the reduction of outpatient 
visits, and ambulatory expenses, over standard therapy7,11,28. 
In South America immunostimulation by injections of killed 
promastigotes plus BCG is used in the treatment of cutaneous 
leishmaniasis. This appears to promote healing even in cases of 
diffuse cutaneous and mucosal leishmaniasis13. Three doses of killed 
L. amazonensis preparation alone provided no protection against CL in 
Colombian soldiers13,32. Current laboratory efforts are focused on novel 
antigens and adjuvants, live-attenuated vaccine, recombinant purified and 
subunit proteins, naked DNA, bacteria expressing Leishmania antigens 
and the targeting of dendritic cells13.
In VL the focus is on the combined administration of a therapeutic 
vaccine with antileishmanial drugs for treatment of PKDL. Use of 
therapeutic vaccine could reduce the dose and duration of chemotherapy29. 
PKDL is a source of the human infection for dissemination of VL 
so the ability to treat this condition could be critical to elimination of 
the disease. Clinical trial guidelines are being generated and vaccine 
candidates and drug regimens are under selection for a clinical trial for 
PKDL in Sudan, for which the estimated completion date is 200929. 
Safe, effective and affordable treatments for VL are urgently needed 
in regions where the disease is endemic, incorporated in formulations 
compatible with administration in rural settings14,24,26,29. 
This report describes the successful treatment with liposomal 
amphotericin B (Ambisome ®) of Colombian girl and boy with VL who 
had previously received pentamidine and N-methyl glucamine regimens 
in the Caribbean coast of Colombia.
Case 1: The patient was a 16 month-old female from the rural 
area of the municipality of Ovejas (department of Sucre, Colombia), 
consulted for the first time on January 9th 1994, having developed 
clinical manifestations during the previous 20 days. These consisted 
of high intermittent fever, chills, sweating, generalized mucocutaneous 
pallor, adynamia, hyporexia, and progressive abdominal distention. She 
was conscious and hydrated, weighing 6.8 kg, with a heart rate of 100/
min, respiratory rate of 36/min and body temperature of 37 ºC. She 
showed a profound mucocutaneous pallor and a globulous abdomen with 
splenomegaly of 5 cm below the left costal margin.
The laboratory test showed anemia, normal leukocyte and platelet 
count, normal urinalysis and coagulation test, negative seroaglutination 
for febrile antigens, with marrow and splenic aspirations being negative 
for Leishmania or any other hemoparasites.
A diagnosis of anemic syndrome was made. Despite having negative 
laboratory tests, the clinical suspicion of leishmaniasis persisted and the 
patient was hospitalized in order to confirm the diagnosis and to allow 
treatment.
The patient was treated with Glucantime® at a dose of 20 mg/kg/
day for a period of 21 days. There was an evident recovery on the fifth 
day of treatment, with diminished fever and pallor. Bone marrow and 
splenic aspirates remained negative until the treatment was completed. 
The patient was released from the hospital in good health.
The patient returned four months later with the same clinical 
manifestations. The splenomegaly had increased to 8 cm below the left 
costal margin; hemoglobin was 4.5 g/dL, hematocrit 13%, and leukocyte 
count 3.3 x 109/L with 40% neutrophils and 60% lymphocytes. Total 
serum proteins, albumin and globulins were normal. Bone marrow and 
splenic aspirates showed abundant amastigotes of Leishmania. The 
patient was hospitalized again and started a new scheme with N-methyl 
glucamine antimoniate at the same dosage. A blood transfusion was 
performed. The patient apparently recovered and the anemia disappeared 
although splenomegaly persisted. The splenic aspirate was negative for 
Leishmania at the end of the treatment.
Six months later, the patient returned having suffered for two months 
from similar manifestations and growth retardation. A splenomegaly of 10 
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cm below the left costal margin was found. The patient was diagnosed with 
antimonial-resistant VL. Laboratory tests revealed anemia and a splenic 
aspirate contained abundant amastigotes of Leishmania. The patient was 
hospitalized again and treated with Glucantime® at a dose of 28 mg/kg/
day for 28 days, no improvement being achieved.
The treatment was changed to Pentacarinat® at a dose of 4 mg/
kg/day over 15 days. The febrile syndrome disappeared but pallor and 
splenomegaly persisted. At the end of the treatment, abundant amastigotes 
of Leishmania were observed in the splenic aspirate and culture results 
were positive. The patient continued to have febrile episodes, with 
persistent pallor and splenomegaly. She was then transferred to a tertiary 
level hospital in Medellin.
Treatment with intravenous liposomal Amphotericin B 
(Ambisome®) was initiated at a dose of 2 mg/kg/day for 21 days. 
Blood tests (Table 1) showed that the patient had pancytopenia as a 
result of VL. The patient showed improvement on the fourth day of 
treatment. Secondary effects included hyperkalemia (6.1 mEq/L) on 
the seventh day of therapy and hypothermia, for which she received 
treatment. Renal and hepatic functions were normal during the 
treatment (Table 2-3). Pancytopenia was corrected after 10 days of 
treatment, and the patient showed a satisfactory improvement. She 
was released from the hospital in good condition, asymptomatic apart 
form splenomegaly. The splenic aspirate was negative for Leishmania 
at the end of the treatment. The patient was followed up for one year 
and remained in good health.
CASE 2: A 3 year-old male from the rural area of Sincelejo 
(Colombia), consulted for first time in March 1995, with clinical 
manifestations developed during the last month, consisting of intermittent 
fever, paleness, adynamia, chills, anorexia, weight loss, increased 
abdominal perimeter, cough, rinorrhea and tachypnea.
VL was diagnosed based on a positive spleen aspirate. Treatment with 
Glucantime® at a dose 20 mg/kg/day during 20 days was initiated. The 
patient received two schemes of such treatment divided by an interval 
of three months. Only partial recovery was obtained and the abdominal 
distension persisted.
One month later, the fever and respiratory signs reappeared and a 
third scheme of Glucantime® at the same dose was administered, without 
a total recovery.
Five months later the paleness, fever, and anorexia returned and he 
was transferred to a third level hospital in Medellin, Colombia. 
The bone marrow aspirate was positive for Leishmania. The treatment 
was changed for Pentacarinat® at a dose of 4 mg/kg/ every other day 
during 18 days.
Table 1
Blood tests (case 1)
Date Hemoglobin 
(g%)
Hematocrit (%) Leukocytes Differential leukocyte count (%) Platelet count 
(mm)
Sedimentation 
(mm/hour)N L AL M E B
1-18-95 3.5 11 2900 12 82 6 0 0 0 63000 160
1-20-95 10.5 33.8 3000 14 80 6 0 0 0 68000 ND
1-25-95 9.4 30.8 2400 10 78 43 3 0 5 54000 117
2-2-95 ND 31 4500 30 60 0 1 3 0 ND 115
2-7-95 ND 31 3200 30 60 4 ND ND ND ND 80
Normal 
values
11-14 33-42 5000-12000 21

66
19

63
4.6

11.2
0

7
0 150000-450000 0-10
N = neutrophils; L = lymphocytes; M = monocytes; E = eosinophils; B = bands; AL = atypical lymphocytes; ND = not done.
Table 2
Hepatic tests (case 1)
Date
Alkaline phosphatase 
(UA/L)
Transaminases
GOT UL GPT UL
1-25-95 ND 16 8
2-2-95 166 22 18
2-8-95 137 34 26
Normal values 100-300 
(1-9 years)
15-55 
(1-9 years)
5-45 
(1-9 years)
ND = not done
Table 3
Renal function tests (case1)
Date Urea nitrogen (mg/dL)
Urea 
(mg/dL)
Serum creatinine 
(mg/dL)
1-25-95 ND ND 0.6
2-1-95 8.4 17.98 0.7
2-8-95 13.3 28.57 0.5
Normal values 5-18 10-45 0.3-0.7
ND = not done
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Five months later he returned in poor condition with growth 
retardation, paleness, weakness, splenomegaly (under the left iliac 
fosse), hepatomegaly (3 cm below the right costal margin), and cervical 
lymphadenopathy; a new marrow aspirate was done and it was positive 
again. The patient was diagnosed as having resistant VL.
Treatment with Ambisome® was administered at a daily dose of 0.6 
mg/kg/day until reaching a total of 15 mg/kg (180 mg). No renal, hepatic 
or blood toxicity was developed and no signs of immunodeficiency 
were found. The fever disappeared on the 4th day of therapy, the 
visceromegalies dimished and the patient recovered.
He was released from the hospital in good condition, asymptomatic 
but with a splenomegaly of 4 cm below the left costal margin (Table 4).
DISCUSSION
VL caused by L. infantum mainly affects young children and is almost 
always fatal if untreated13,22,23. Effectiveness of sodium stibogluconate 
for VL and CL has been declining during the last two decades, with 
37-64% of the patients with VL in India currently failing to be cured by 
antimony treatment13,14,22. This drug is highly toxic and requires long-term 
parenteral treatment12,13,14,24,25. 
Alternative chemotherapy treatments are pentamidine and 
amphotericin B, both of which are also toxic. However the declining 
efficacy of pentamidine leaves amphotericin B as the only alternative 
for these Sbv-refractory patients12,13,24,25. 
Immunochemotherapy (vaccine with antileishmanial drugs) is maybe 
an alternative treatment for those patients for whom SbV compounds are 
not indicated, clinical trial guidelines are being generate7,11,16,28. 
Amphotericin B is a polyene macrolide antibiotic that binds to sterols 
in cell membranes. It is the most active antileishmanial agent in use. Its 
infusion-related and renal toxicity may be reduced by lipid-based delivery. 
Liposomal amphotericin B (Ambisome®), a complex of amphotericin 
B and distearopalmitoglicerol bound to a liposome of cholesterol and 
phosfatidylcoline, seems to be less toxic than other amphotericin B lipid 
formulations such as Amphocil® and Amphotec®5,12,14,17.
Liposomal Amphotericin B (Ambisome®) is approved for treatment 
of leishmaniasis in studies coordinated by WHO/TDR16. Its principal 
advantage is its high effectiveness, mitigated somewhat by its high price. 
In India it is currently available at $ 4 dollar 1 /mg, almost 3000 times 
higher that the unit cost of sodium stibogluconate price and 900 times 
more than that of paromomycin. A preferentially low price of $ 22.3 per 
ampoule (approximately $ 0.47mg, or one-tenth of the official price) has 
been secured by Médecins Sans Frontières, although this is currently not 
applicable to India14. Liposomal Amphotericin B was selected as the first 
choice of treatment for VL in the outbreak of the disease that appeared 
in Ethiopia in 2006 (MSF, personal communication).
The only major restriction on the current use of Amphotericin B 
is its cost, but this can be compensated by benefits of low toxicity and 
reduced time required for hospital interment12,13,22. However in 2007 the 
WHO signed an agreement with the manufacturer to produce the drug 
at $20 per vial for VL treatment14.
Failure with antimonial compounds treatment can be generated by 
different causes, among them, host factors such as the immune response, 
physiological disorders that alter the tissue deposits of the antimoniate 
and genetic predisposition for not responding to antimoniate therapy. 
Resistance of Leishmania against a given drug may be either natural, 
or may be acquired when the parasites are exposed to sub-optimal drug 
doses20. In our patients, the therapeutic scheme was that recommended 
by experts so the resistance cannot be attributed to a resistant strain that 
survived a low initial dose.
In the absence of effective vaccines and vector control measures, 
the main line of defense against the disease is chemotherapy. Organic 
pentavalent antimonials have been the first-line drugs for the treatment 
of leishmaniasis for the last six decades, and clinical resistance to 
these drugs has emerged as a primary obstacle to successful treatment 
and control2,20,23,29. A multiplicity of resistance mechanisms has been 
described:1,2,20 Leishmania infection is classically associated with a 
depression of T helper type 1 (Th1) cells and preferential expansion 
of T helper type 2 (Th2) cells and accordingly, skewing of T helper 
cells towards a Th1 response is considered as a promising therapeutic 
strategy32. In the Th1 response, T cells activate macrophages by 
releasing the cytokines interferon (IFN)-γ and interleukin (IL)-2. In 
the Th2 response, T cells release cytokines IL-4, IL-5, IL-10 and 
transforming growth factor (TGF)-β which inhibit macrophages from 
killing Leishmania spp.5.
Table 4
Laboratory test (case 2)
Date
TEST
Hb Hct L N Lym E Plat Na K Cr
29-01-96 7.5 24 5600 40 55 5 250000 136 4.3 0.5
02-03-96 10.4 31 6600 34 56 10 202000 ND ND ND
05-03-96 11.2 34 11600 39 50 11 286000 139 3.6 0.5
Normal 
values
11-14 33-42 5000-12000 21-66 19-63 0-7 150000-450000 139-146 3-6 0.3-0.7
Hb = Hemoglobin (g/100mL); Hct = Hematocrit (%); L = Leukocytes; N = Neutrophils (%); Lym = Lymphocytes (%); E = Eosinophils %; Plat = 
Platelet count; Na = Sodium (mE/L); K = Potassium (mE/L); Cr = Serum Creatinine (mg/dL); ND = Not done.
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Although the macrophage has effective mechanisms to decimate 
intracellular pathogens by generating toxic metabolites like nitric oxides 
and reactive oxygen species for which their activation by interferon-
gamma (IFN-γ), released by Th1 cells is mandatory, Leishmania is 
a devious pathogen that evades the immune response by selectively 
attenuating pro-inflammatory signalling pathways25.
VL patients require an IFN-γ dominant Th1 pro-inflammatory 
response for clearing the parasite. IFN-γ switches on a number of immune 
effector pathways to activate lytic mechanisms within the macrophage, 
thus facilitating immune containment of the parasite load. On the other 
hand, induction of an IL-4-biased (Th2 response) antagonizes Th1 
protective, and inhibits the immune control in vivo leading to severe 
disseminated forms of the disease. The IL-4 excess production in 
susceptible hosts probably causes drug unresponsiveness27. 
Progressive non-healing infection (eg, VL, PKDL, and chronic 
cutaneous leishmaniasis) seems more likely to indicate a net suppressive-
type response (eg, Th2 > Th1) rather than an inert Th1 response; under 
either condition, cell-mediated immunity would be ineffective13.
The importance of the Thl-Th2 paradigm in the pathogenesis of 
leishmaniasis has been an area of intense investigation. The susceptibility, 
resistance, and immunopathogenesis of L. donovani infection largely 
depends on the cytokine profiles elicited after infection27.
Metalloid containing drugs (arsenic and antimony) are used to 
combat infectious diseases caused by pathogenic parasites, to survive 
in such a hostile habitat, it is crucial to develop strategies to exclude 
toxic substances from the cell and to acquire tolerance. Cells remove 
metalloids from the cytosol either by active efflux or by sequestration in 
an integral organelle. Controlling the influx appears to be another way 
of maintaining a low intracellular metalloid content. The emergence of 
resistance to metalloid-containing drugs is a serious threat to effective 
medical treatment20.
SbV is reduced to trivalent antimony SbIII, which constitutes the 
active form of the drug against the parasite. Once SbIII is within the cell, 
it would be conjugated to trypanothione, the parasite- specific spermidine 
glutathione conjugate. Trypanothione is found to be increased in arsenite 
and antimoniate resistant cells. This Sb trypanothione conjugate could 
then be sequestered inside a vacuole by the ATP binding cassette (ABC) 
transporter PGPA or extruded from the cell by a thiol-X pump. Altered 
transport of metals avoids the normal function of the antimonials6,20.
In VL or “kala-azar” caused by L. donovani, man is the main reservoir, 
and selection of resistant strains as a consequence of improper dosages 
allows their expansion in the human population by means of bloodffeding 
by sand flies15. It has not been demonstrated that immunocompetent 
individuals infected with L. infantum can play a role as reservoirs. 
A different situation occurs in immunocompromised host, in which 
cases of coinfection with HIV and L. infantum are more frequent. The 
parasite is usually found in peripheral blood and skin, which enables 
humans to infect vectors3,18,19. This exposes a new and more dramatic 
problem since these patients showed a poor response due to host factors 
and therapeutic regimens; they would have select for resistant strains 
and also act as reservoirs to disseminate them2.
In Colombia in 2005 18097 cases of leishmaniasis were reported, 
of which 17983 were CL (99.4%), 60 (0.3%) were mucocutaneous, and 
54 (0.3%) VL. The age group most affected was that of patients aged 
15-44 years old (81.3%)13. In 2006 16238 cases of leishmaniasis were 
reported, 11.2% less than in 200510.
 In other countries where L. infantum is endemic, this parasite can 
cause two clinical syndromes: VL and CL. CL has been treated with 
low dosages of pentavalent antimoniate, which would select for resistant 
strains2. Furthermore, epidemiological studies have demonstrated that 
humans can infect sand flies when they bite cutaneous lesions. This could 
represent a mechanism for the spread of resistant strains of L. infantum 
that previously caused cutaneous lesions but then become able to produce 
VL in other patients15,19.
In Colombia 50 cases of VL are diagnosed every year, 90% of 
them in children under the age of five9. These two cases of resistance to 
treatment provide a warning of the possible appearance of resistance to 
antimonials in this region, where it has been also found that L. infantum 
together with L. braziliensis causes cutaneous lesions21.
The first reported case of abnormal response to SbV treatment in a 
Colombian patient with CL produced by L. panamensis was in 1989. 
This patient was treated with 3 Sbv schemes, each of 10 days over a 14 
month period and received more than 92 g of SbV in a wide variety of 
schemes without reaching clinical cure21.
This report is important because it describes the first two Colombian 
cases of VL by L. infantum with no clinical response to the antimonial 
compound, under the recommended scheme of treatment. As can be 
seen, Liposomal Amphotericin B produced an excellent clinical and 
parasitological response, which persisted for a follow-up period of over 
12 months. 
The mechanisms that precluded a good clinical response in these 
patients is not clear, because they did not manifest any of the clinical 
conditions that could normally result in relative resistance. These include 
such as immunodeficiency, severe malnutrition or severe infections 
(tuberculosis or others). 
RESUMO
Dois casos de leishmaniose visceral da Colômbia, resistentes ao 
tratamento com antimoniato de meglumina 
A leishmaniose visceral (VL) afeta aproximadamente 500000 pessoas 
anualmente no mundo. A doença ocorre no mediterrâneo, na América 
Central e na América do Sul, sendo causada por Leishmania infantum 
(syn. L. chagasi). Na Colômbia VL é uma doença endêmica, presente no 
litoral do Caribe e no Vale do rio Magdalena sendo que 90% de casos de 
VL ocorrem em crianças menores de cinco anos. O principal tratamento 
é a quimioterapia com compostos de antimoniais pentavalentes, incluindo 
stibogluconato de sódio (Pentostam®) e antimoniato de meglumina 
(Glucantime®). Estes compostos são os mais usados na Colômbia em 
dosagem de 20 mg/kg/dia durante 28 dias. Entretanto, a resistência de 
L. infantum aos antimoniais pentavalentes está se tornando problema 
importante. Na Colômbia não existiam relatos de casos de VL resistentes 
aos antimoniais pentavalentes. Este trabalho descreve os dois primeiros 
casos colombianos de VL resistentes aos compostos antimoniais em uma 
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menina e um menino, que foram tratados com regime de Pentamidina 
e Glucantime®, e demonstra o sucesso obtido no tratamento com 
anfotericina B liposomal.
Em conclusão, sugerimos como primeira opção de tratamento a 
anfotericina B liposomal porque é altamente efetiva no tratamento da VL, 
dada sua baixa toxicidade, curtos períodos de administração e o baixo 
preço obtido pela organização Médicos Sem Fronteiras.
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